SBIR/STTR Research Award

Label-Free High-Throughput Screening Platform

Award identifier 47d1c15b23c3e4c4b75693ab7378c43dcc7bf6760176c1a30cd8c760ca9d5db4Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$713,506

Program and phase

SBIR · Phase II

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOPRAXIS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): High-throughput screening (HIS) assays for drug discovery and development rely on labels to determine whether a compound binds to the drug target. Label-based assays are time- and labor-intensive, yield limited information, and consume large amounts of expensive biomolecules and chemical libraries. Almost every target requires a different assay; and each new assay can take a year or more to develop. In fact, assay development has become the bottleneck in drug discovery and development, and constitutes a large chunk of the total costs. This SBIR program will develop a label-free, mix-and-measure platform assay, called ?SERS that can be used with any biomolecule target to detect the binding of any small ligand, with little or no assay development. Phase I showed ?SERS is exquisitely sensitive; can detect molecules in the 100-500 Da size range binding to enzymes, lectins, and DMA; can produce information on the binding chemistries involved; and is free from many artifacts that affect other label-free assays. On Phase II, the sensitivity will be improved even further, to enable high-throughput analysis; the assay will be miniaturized, so that only traces of biomolecules and compound libraries are consumed; and demonstrated with a wide range of biomolecules, including DMA, carbohydrates, and diverse proteins. Phase II will also showcase the ability to collect data from complex interactions involving two ligands, monitoring the amount of each ligand that binds, and their impact on each other and on the biomolecule. This platform will have many applications, including cost-effective high-throughput screening for drug lead identification and optimization; rapid in vitro adsorption, distribution, metabolism, and excretion (ADME) and toxicity assays; chemoproteomics (protein interaction profiling with small ligands); and functional glycomics (carbohydrate binding interactions). The platform will be simple to use, very low-cost, and produce a rich body of information on the binding interactions.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.